São Paulo, October 23, 2024 – Eurofarma, a pharmaceutical company that is a leader in innovation in Brazil and one of the main references in generic medicines, was featured in the Folha Top of Mind survey conducted by Datafolha, the research institute of Folha de S. Paulo. The recognition was in the Generic Medicines category, with the company ranking among the five brands most remembered by consumers.

Leandro Forato, Marketing Manager, and Sérgio Santos, Product Manager, both from the Generics Unit, received the award on behalf of Eurofarma

With 52 years of history, the company’s mission is to promote access to healthcare and quality of life through fairly priced treatments. This is precisely where its generics business unit plays a major role, with a portfolio of 117 products distributed across 85,000 points of sale throughout Brazil, reaching a significant number of locations and being present in the vast majority of pharmacies, both chain and independent.

“Our presence is also strong in the outskirts of large urban centers and in the North and Northeast regions of Brazil. We understand that this combination of factors leads consumers and physicians to trust the products we develop and keeps the brand present in consumers’ memories. We are very happy to be part of this ranking,” says Donino Scherer, Director of Eurofarma’s OTC and Generics Business Unit.

Folha Top of Mind is the largest brand-focused survey in Latin America, based on consumer opinion. In 2024, it reached its 34th edition and was conducted by Datafolha across all Brazilian states. The brand awareness survey covered 82 categories of products and services, highlighting companies that secured an important place in the public’s memory. The award ceremony took place on October 22 at Tokio Marine Hall.

To learn more about Eurofarma and its performance in the generic medicines segment, visit: eurofarma.com.br/relatorio-anual

About Eurofarma

Founded in 1972, Eurofarma operates in the healthcare sector through the production and commercialization of products and services aimed at improving people’s quality of life. With a focus on generating shared value, the company covers the main pharmaceutical segments, including medical prescription, OTC and personal care, generics, hospital, oncology, and animal health, in addition to providing third-party manufacturing services. With broad therapeutic class coverage, its portfolio includes more than 2,000 products and 3,700 SKUs (presentations), serving the main medical specialties.

A leader in medical prescriptions in Latin America and Brazil, where it also holds the second position in generics, Eurofarma is present in 22 countries, with full coverage across Latin America and operations in the United States and Africa. The company has 12,600 employees and 11 manufacturing plants, with total production of 573 million units in 2023. In the same year, it invested more than BRL 680 million in innovation and achieved total net revenue of BRL 9.1 billion. Over the past 15 years, Eurofarma has recorded average annual growth of 17%.